Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that a novel nanolipogel with moderate rigidity (NLG-2.5) enhances transdermal delivery of fucosterol, displaying superior permeability, targeting hair follicles, and promoting hair growth in androgenetic alopecia model mice by inhibiting inflammation and androgen pathways and promoting angiogenesis.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This study found that a newly developed peptide, FOL-005, significantly inhibited hair growth and counteracted minoxidil's effects in organ-cultured human male scalp skin and mouse models, without apparent toxicity.

FOL-005 peptide may help treat excessive hair growth safely.

Minoxidil topical foam is a better, less irritating treatment for hair loss.

In this study, fibroblast growth factors promoted dermal papilla cell proliferation and showed potential for treating androgenic alopecia, with possible advantages over minoxidil in cellular organization and health.

This study found that collagen sponges with polyglycolic acid fibers support proper skin and hair follicle restructuring, suggesting potential usefulness for hair reconstitution research and clinical applications.

In a murine model of androgenetic alopecia, this study found that the newly designed IGF-1 biomimetic peptide Ac-GFFY-IGF led to faster and superior hair regrowth compared to minoxidil, suggesting potential for improved human therapies.

In this study, researchers found that a propylene glycol-free and alcohol-reduced topical foam containing minoxidil and finasteride remained chemically, physically, and microbially stable for 180 days when stored properly at room temperature in light-resistant containers.

This study found that a bleach bath treatment with 0.005% HOCI reduced the expression of certain serine proteases in cultured keratinocytes and lowered skin pH in atopic dermatitis patients, potentially improving symptoms by modulating the NF-kB pathway.

In a clinical phase I/IIa study, subcutaneous injections of the peptide FOL-005 increased hair growth by 8% and were safe for treating alopecia.

This study developed a stable, cosmetically appealing formulation for the topical delivery of the peptide FOL-005, enhancing skin permeation and maintaining stability by keeping the peptide solid and in a water-free environment with particle sizes under 10 µm.

5% minoxidil foam helps women with thinning hair.

This study identified the osteopontin-derived peptide, FOL-005, as a potential inhibitor of unwanted human hair growth by promoting catagen development without reducing stem cell numbers or showing toxicity.

The two lotions used day and night may be a good alternative to minoxidil for hair loss treatment with better cosmetic effects and tolerance.

A woman with frontal fibrosing alopecia experienced unusual hair growth after using a specific topical lotion.

This study found that combining plasma rich in growth factors with conventional treatment significantly improved hair regrowth and reduced symptoms in patients with frontal fibrosing alopecia compared to conventional treatment alone.

This study found that topical corticosteroid foams are effective and generally preferred by patients for a variety of corticosteroid-responsive skin conditions, demonstrating significant clinical benefits such as improved psoriasis symptoms and hair regrowth in alopecia areata compared to traditional forms.

In this study, researchers developed a composite paste system using minoxidil-loaded nanoparticles and valproic acid, enhanced by roller-microneedles, which significantly stimulated hair regeneration and perifollicular vascularization in an androgenetic alopecia mouse model, reducing side effects compared to traditional treatments.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

This study demonstrated that fibrin hydrogels support skin-derived precursors in hair follicle neogenesis in mice, with new hair growth and regeneration of blood vessels and sebaceous glands observed.

This study found that a minoxidil foamable emu oil emulsion significantly promoted hair growth in animals compared to a marketed 5% minoxidil solution, showing increased hair follicles in the anagenic phase.

This study found that a cosmetic foam reduced the telogen rate in men with androgenetic alopecia, suggesting a potential benefit against male pattern hair loss.

PP405 may help hair growth by activating hair follicle stem cells.

This study found that 5% minoxidil topical foam used once daily for 24 weeks was well tolerated and significantly improved hair regrowth and scalp coverage in women with female pattern hair loss compared to vehicle foam.

This article discusses inflammatory perifollicular fibrosis and alopecia but provides no new research findings.

This study found that a novel peptide, FOL-005, derived from osteopontin, significantly inhibited hair growth in human hair follicles both ex vivo and in vivo, suggesting potential as a treatment for unwanted hair growth.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.